All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2021; the latest 2024-08-01.
From the record
Virax Biolabs Group Limited's filings since 2021 show 2 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2024-08-01) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-52.4% a year over 5 filed years; profitable in 0 of 5.
From the record
Virax Biolabs Group Limited's 5 filed years say what it did: revenue went from $124 thousand in fiscal 2021 to $6 thousand in fiscal 2025, down 52.4% a year; it rose in 1 of 3 years; the deepest fall was 100% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 5 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 3.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Virax Biolabs Group Limited's shareholder treatment is put at 3.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 36% of 18 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -111%: lost 111¢ per shareholder dollar. Leverage 15%: owes 15¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-03-31, Virax Biolabs Group Limited lost about 111 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 1 cents per dollar of everything the company owns. Leverage: it owed about 15 cents per dollar of assets, and net share issuance: its share count grew 85.9% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 3% of 17 in its family; net margin -95833.7%.
From the record
Virax Biolabs Group Limited's standing among 17 graded names in its industry family: revenue of $6 thousand in fiscal 2025 ranks in the bottom 3% by size; a net margin of -95833.7% ranks in the bottom 3% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 4.6/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Virax Biolabs Group Limited's leadership is put at 4.6 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 15 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
bottom 49% of 16 in its family for room to expand.
From the record
Virax Biolabs Group Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against no long-term debt tagged leaves 65.8% of its assets as net cash, top 8% of its family; cash from operations less capital spending is -81621.6% of revenue (bottom 3%); a gross margin of -838.2% (bottom 4%); research spending of 28112.5% of revenue (top 3%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 44% of 17 in its family for growth drivers.
From the record
Virax Biolabs Group Limited's growth drivers, from the filed years to fiscal 2025: the newest year grew -96% (bottom 3%); research spending grew 60.1% a year (top 9%); capital spending grew -36.6% a year (bottom 37%) (its annual reports). Virax Biolabs Group Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 13% of 16 in its family for expectations against reality.
From the record
Virax Biolabs Group Limited's newest year against its own record: net income of $6 million against a prior three-year average of $5 million (bottom 22%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 3%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made